Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Gene therapy programme launched for neurodegenerative diseases
Fri July 30th - An innovative gene therapy programme has been launched that could lead to novel treatments for neurodegenerative diseases. More
Unvaccinated pregnant women hospitalised with COVID-19
Fri July 30th - Pregnant women are being urged to have the COVID-19 vaccination after 200 were admitted to hospital last week with the virus – almost all of whom were unvaccinated. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Hope for new psoriasis treatment

Friday October 30th 2020

A possible new therapy for psoriasis has shown promise, a European conference has heard.

A phase 1b clinical study shows the first clinical evidence that modulating systemic inflammation can be treated orally with a non-living single strain commensal microbe, researchers say.

The findings of the study, which were presented at a conference of the European Academy of Dermatology and Venereology, evaluated EDP1815, an orally-delivered investigational therapy that is being developed for treatment of inflammatory diseases but has never been used for a human disease before.

Researchers tested a preparation of a non-living single strain of the bacterium Prevotella histicola, isolated from the small intestine of a human donor, in two cohorts of 12 and 18 patients with mild to moderate psoriasis for 28 days, with follow-up off treatment through 42 days.

Early results showed that EDP1815 was well tolerated at daily doses of up to 8.0x101 cells administered for up to 28 days.

At day 28, the mean percentage reduction in Psoriasis Area Severity Index (PASI) score for both EDP1815 cohorts was 16%, compared to 1% for the placebo cohorts. There was an improvement to 21% in the high-dose cohort at day 42, but not the low dose cohort (10%) or placebo cohorts (3%), indicating sustained and ongoing clinical effect at the higher dose.

The mean reduction in Lesion Severity Scores (LSS) at 28 days were 15% and 23% in the high- and low-dose cohorts, respectively, compared to a 1% increase from baseline in the placebo group. Again, further clinical improvement, to a 24% reduction, was seen in the high-dose cohort.

Dr Douglas Maslin, of Addenbrooke’s Hospital in Cambridge, UK, said: “Although several treatments options are available for psoriasis patients with the most severe disease, there is a great need for new innovative methods for those living with mild-moderate disease.

"It is a real breakthrough, especially as we have seen from the pre-clinical and phase I trials that it was well tolerated with no overall difference from placebo and with no severe side effects reported. We are extremely encouraged to see that these data support further clinical development of EDP1815 in psoriasis. We are already in phase II clinical trials across the UK, Poland and US. This is a potentially massive win for the majority of psoriasis patients, as it has the potential to improve treatment options and perhaps change the current standard of care.”

* EADV Virtual will also hear from Italian researchers who found that biologics increase the risk of COVID-19 infection in psoriatic patients but could protect them from ICU hospitalisation and death.

The study compared 1,193 adult psoriatic patients receiving biologics and small molecules at San Donato Hospital in Milan with the population in Lombardy from 21 February 2020, when the first COVID-19 case was recorded in Italy, to 9 April 2020.

Compared with the general population of Lombardy, patients receiving biologics were at higher risk of testing positive for COVID-19 (unadjusted OR 3.43 [95%CI 2.25-5.73], p<0.0001), being self-quarantined at home (OR 9.05 [95%CI 5.61-14.61], p<0.0001) and being hospitalised (unadjusted OR 3.59 [95%CI 1.49-8.63], p=0.0044).

However, their risk of being admitted to ICU (unadjusted OR 3.41 [95%CI 0.21-54.55], p=0.3861) and of dying (unadjusted OR 0.41 [95%CI 0.03-6.59], p=0.5306) were not statistically significant.

Tags: Dermatology | Europe | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)